Sol-Gel Technologies, Perrigo to collaborate on 3 new generics
Sol-Gel Technologies, a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, has entered into collaborative agreements with Perrigo for the development, manufacturing and commercialization of three new generic product candidates.
Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the Food and Drug Administration for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidates in the United States. Sol-Gel and Perrigo will share the development costs and any gross profits generated from potential sales of the generic product candidates.
“Just a year ago, Sol-Gel entered into a seventh agreement with Perrigo to develop, manufacture and commercialize two generic formulations and we are thrilled to now expand the collaboration to cover these three, new product candidates,” said Sol-Gel CEO Alon Seri-Levy. “Our collaboration with Perrigo is generating meaningful revenue for Sol-Gel as we continue to focus on the submission and commercialization of our own branded product candidates Epsolay and Twyneo, which we expect to file NDAs for in the second quarter and second half of this year, respectively.”
Separately, Sol-Gel said that Bausch Health filed a patent infringement action regarding Perrigo’s ANDA for a generic version of Bryhali (halobetasol propionate) lotion, 0.01%, for the treatment of plaque psoriasis in adults. The halobetasol propionate lotion, 0.01%, development is covered under a previous collaboration between Sol-Gel and Perrigo.